01 April 2008
Randomized comparison of metoprolol versus conventional treatment in preventing recurrence of vasovagal syncope in children and adolescents
Qingyou Zhang, Hongfang Jin, Li Wang, Jianjun Chen, Chaoshu Tang, Junbao DuMed Sci Monit 2008; 14(4): CR199-203 :: ID: 850297
Abstract
Background: Previous studies that have assessed the effects of beta blockers on preventing vasovagal syncope provide conflicting results. We sought to evaluate the effectiveness of metoprolol versus conventional treatment in preventing the recurrence of syncope in children and adolescents.
Material/Methods: Twenty-eight children and adolescents (8 boys, 20 girls; mean age, 12±3 years; age range, 8–17 years) with vasovagal syncope were randomized to receive either metoprolol (metoprolol group; dosage range, 0.5–1.5 mg/kg/d) or conventional treatment (control group) for 1 year. The main outcome measure was the first recurrence of syncope beginning 2 weeks after the start of treatment. The mean follow-up was 22±10 months. Time to first recurrence of syncope was analyzed using Kaplan-Meier curves and compared with a log-rank test.
Results: The 2 groups did not differ in terms of clinical characteristics. The number of syncopal episodes before tilt testing was 8±6 in patients in the metoprolol group and 9±6 in patients in the control group (P=0.150). Syncope recurred in 6 of 14 children in the metoprolol group and in 4 of 14 children in the control group. No significant between-group differences were found regarding the probability of freedom from a recurrent episode of syncope during follow-up (metoprolol vs controls, 43% vs 29%; P=0.389), as demonstrated by Kaplan-Meier curve analyses.
Conclusions: Recurrence of vasovagal syncope in children and adolescents treated with metoprolol is similar to that of patients treated with conventional therapy.
Keywords: Child, Adolescent, Metoprolol - therapeutic use, Recurrence - prevention & control, Syncope, Vasovagal - therapy
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952